With actionable results using an accurate predictive and prognostic test with LoE1A in ESMO Guidelines
How to Predict Recurrence of Early-Stage Breast Cancer
A comprehensive tool for breast cancer treatment decisions Genomic testing for breast cancer recurrence is guiding critical treatment decision making in early stage breast cancer. It helps clinicians to personalize treatment and avoid unnecessary side effects, ensuring each woman receives the therapy that’s right for her.
EndoPredict is a genomic test that accurately predicts the risk of recurrence in early-stage ER-positive, HER2-negative (ER+/HER2–) breast cancer – up to 15 years after diagnosis. It also indicates whether a patient is likely to benefit from chemotherapy, helping guide truly personalized treatment decisions.
EndoPredict® Uses Molecular Biology and Clinical Pathological Factors to Help Answer Critical Treatment Questions
By combining three key factors – a molecular score, tumor size, and nodal status – EndoPredict provides more prognostic information than first-generation tests that assess gene expression alone.
EndoPredict includes genes specifically validated to predict both early and late distant recurrence in ER+/HER2– breast cancer, offering valuable guidance for long-term treatment planning.
A More Accurate Decision-Making Tool for Breast Cancer Treatment Decisions
How Does EndoPredict® Compare to Other Genomic Tests?
Not all breast cancer tests provide the same insights. Differences in clinical validation, long-term risk prediction, and guidance for chemotherapy decisions can significantly impact patient care. EndoPredict stands out with reliable evidence, including long-term follow-up data and proven chemotherapy benefit prediction in ER+/HER2- early-stage breast cancer. Compare leading genomic tests to understand what sets EndoPredict apart – and why test selection is critical for optimized patient care.